RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

Home・Listă Acțiuni・Lonza Group AG

Lonza Group AG

Închisă

SectorSănătate

493.4 3.09

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

478.65

Maxim

494.2

Indicatori cheie
By Trading Economics
Venit	57M 483M
Vânzări	-621M 3B
P/E Medie Sector	37.585 67.147
Randament dividend	1.04
Marjă de profit	16.345
Angajați	20,000
EBITDA	-181M 822M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+37.73% upside

Dividende
By Dow Jones
Randament dividend Medie Sector	1.04% 2.36%
Următoarele câștiguri	22 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-4.6B 34B
Deschiderea anterioară	490.31
Închiderea anterioară	493.4

Sentimentul știrilor

By Acuity

14%

86%

24 / 347 Clasament în Healthcare

Lonza Group AG Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

6 mar. 2026, 17:44 UTC

Achiziții, Fuziuni, Preluări

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

28 ian. 2026, 06:15 UTC

Câștiguri

Lonza Sales Grow on New Contract Momentum

23 iul. 2025, 08:30 UTC

Câștiguri

Principalele dinamici ale pieței

Lonza Shares Rise After Outlook Lift for Core Business

9 mar. 2026, 10:34 UTC

Market Talk

Lonza Might Disappoint Investors With Capsule Business Valuation -- Market Talk

6 mar. 2026, 17:12 UTC

Achiziții, Fuziuni, Preluări

Correct: Lonza to Sell Capsules & Health Ingredients Business to Lone Star Funds

6 mar. 2026, 17:10 UTC

Achiziții, Fuziuni, Preluări

Lonza: Total Undiscounted Proceeds Expected to Be at or Above CHF3B

6 mar. 2026, 17:09 UTC

Achiziții, Fuziuni, Preluări

Lonza to Retain 40% Stake in CHI

6 mar. 2026, 17:08 UTC

Achiziții, Fuziuni, Preluări

Lonza Will Receive Upfront Proceeds of CHF1.7B

6 mar. 2026, 17:07 UTC

Achiziții, Fuziuni, Preluări

Lonza: Transaction Expected to Close in 2H

6 mar. 2026, 17:07 UTC

Achiziții, Fuziuni, Preluări

Lonza: This Is for Enterprise Value of CHF2.3B at Closing

6 mar. 2026, 17:06 UTC

Achiziții, Fuziuni, Preluări

Lonza to Sell Capsules & Health Ingredients Business Lone Star Funds

28 ian. 2026, 12:04 UTC

Market Talk

Câștiguri

Lonza Results Show a Company in Good Shape -- Market Talk

28 ian. 2026, 05:35 UTC

Câștiguri

Lonza Anticipates 2026 Core EBITDA Margin to Reach Level Above 32%

28 ian. 2026, 05:34 UTC

Câștiguri

Lonza Anticipates 2026 Sales Growth of 11-12% at CER

28 ian. 2026, 05:33 UTC

Câștiguri

Lonza Issues 2026 View

28 ian. 2026, 05:32 UTC

Câștiguri

Lonza 2025 Core Ebitda Margin 31.6%

28 ian. 2026, 05:32 UTC

Câștiguri

Analysts Saw Lonza 2025 Core Ebitda at CHF2.27B

28 ian. 2026, 05:32 UTC

Câștiguri

Lonza 2025 Core Ebitda CHF2.06B

28 ian. 2026, 05:30 UTC

Câștiguri

Analysts Saw Lonza 2025 Sales at CHF7.54B

28 ian. 2026, 05:30 UTC

Câștiguri

Lonza 2025 Sales CHF6.53B

27 oct. 2025, 08:24 UTC

Market Talk

Lonza on Track to Meet Long-Term Goals -- Market Talk

23 oct. 2025, 10:53 UTC

Market Talk

Câștiguri

Lonza Set to Recover as Contracts Flow in -- Market Talk

23 iul. 2025, 08:00 UTC

Market Talk

Câștiguri

Lonza Nudges Up Full-Year Guidance for Core Business After Good Results -- Market Talk

23 iul. 2025, 04:44 UTC

Câștiguri

Lonza 1H Sales Grew 19% at Constant Currency

23 iul. 2025, 04:43 UTC

Câștiguri

Lonza 1H Core Ebitda Margin 29.6%

23 iul. 2025, 04:43 UTC

Câștiguri

Lonza: Margins Will Be Only Minimally Affected

23 iul. 2025, 04:42 UTC

Câștiguri

Lonza Expects FX Headwind of -2.5% to -3.5% on 2025 Sales and Core Ebitda

23 iul. 2025, 04:42 UTC

Câștiguri

Lonza: This Is Mainly From Weakening of U.S. Dollar

23 iul. 2025, 04:38 UTC

Câștiguri

Lonza 1H Net Pft CHF426M

23 iul. 2025, 04:37 UTC

Câștiguri

Lonza Backs 2025 View for CHI Business

Comparație

Modificare preț

Lonza Group AG Așteptări

Obiectiv de preț

By TipRanks

37.73% sus

Prognoză pe 12 luni

Medie 660 CHF 37.73%

Maxim 670 CHF

Minim 630 CHF

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLonza Group AG - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

4 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 4 analiști care au acordat evaluări ale acțiunilor Lonza Group AG - Dist în ultimele 3 luni.

Sentiment

By Acuity

24 / 347 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.